The burden of chronic cough often goes far beyond the cough itself for patients living with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung diseases (non-IPF ILDs). From having to stop working, to the physical pain that comes from coughing, to removing themselves from everyday activities like going out to dinner or to the movies, the toll cough has had on their lives is evident. Hearing firsthand from Steve, Renée, Theresa and Ron, their stories highlight just how broad the impact of chronic cough can be on patients and their families. Thank you to Steve, Renée, Theresa and Ron, for sharing their stories with us, along with so many others who continue to speak up and help others feel seen and heard. #ChronicCough #IPF #ILD #PatientVoice #VoicesofChronicCough #caring4cough

Adjunctive Prednisolone for Kawasaki Disease An NEJM study has shown that glucocorticoids provide no added benefit when added to standard primary treatment in Kawasaki disease patients. https://buff.ly/CutKShB

Adjunctive Prednisolone for Kawasaki Disease An NEJM study has shown that glucocorticoids provide no added benefit when added to standard primary treatment in Kawasaki disease patients. https://buff.ly/OAegHFk

The impact of chronic cough can extend beyond the cough itself leading to a large burden for many patients with idiopathic pulmonary fibrosis (IPF) and non-IPF interstitial lung diseases (non-IPF ILDs). This constant cough can lead to physical, emotional, and social impacts on patients. Learn more about the burden of chronic cough: https://ow.ly/qB6N50YXQ9W

#Breaking: We are excited to share positive results from our Phase III trials evaluating our investigational BTK inhibitor in people living with relapsing multiple sclerosis (RMS). For the more than 2.9 million people living with multiple sclerosis (MS) worldwide, this data brings our research and development strides into focus, representing a potential new approach to MS with comprehensive disease control. Learn more: http://spr.ly/6046BB8uD8

Liver disease often progresses silently. Many patients with advanced fibrosis may feel completely well until disease progression becomes significant — limiting opportunities for earlier intervention. This is why identifying at-risk patients earlier matters. In MASLD care, screening is not about testing everyone. It is about ensuring the right patients are not missed before disease advances. Earlier detection supports earlier action — and better patient outcomes. #Screening #EarlyDetection #MASLD #LiverHealth #PreventiveCare #LIVERFASt #Diagnostics

STING gain-of-function has primarily been described to cause pediatric-onset disease. In a new study in Journal of Human Immunity, Thomas R. Riley, Jonathan J. Kotzin, Amanda Finck, Jonathan Miner and colleagues (University of Pennsylvania) report a surprisingly high prevalence of adult-onset #SAVI among patients with common #autoimmune disease diagnoses. https://lnkd.in/eEVjcy8c #Autoimmunity #IEIs

Thrilled to share our new paper in the Journal of Human Immunity. 🧬 By examining exomes from the Penn Medicine Biobank, we found a surprisingly high prevalence of STING gain-of-function variants in adults. Unlike classic SAVI — characterized by severe early-onset disease and high mortality — these adult carriers showed a spectrum of penetrance, ranging from asymptomatic to overt autoimmune disease. Adult-onset SAVI is hiding in plain sight, and our findings show that common autoimmune and autoinflammatory diseases can be caused by STING gain-of-function mutations. Thanks to the entire team at Penn, especially our first authors Thomas Riley and Jonathan Kotzin, and to Jonathan Miner for leading this work. Check it out here —> https://lnkd.in/exhZUuJi

Inhibrx Biosciences, Inc. has reported updated interim results from its Phase 1/2 study of #ozekibart plus FOLFIRI produced a 20% objective response rate and an 87% disease control rate in heavily pretreated metastatic #colorectalcancer, where historical response rates are typically 1% to 6%. In 45 evaluable patients, the median progression-free survival was 5.5 months, and 42% remained progression-free at six months. The regimen also showed a manageable safety profile, with mostly Grade 1 or 2 treatment-related adverse events. https://lnkd.in/eEAEnkc4

Could it be more than osteoporosis or fibromyalgia? 👀 In this RhAPPcast episode, Amanda Mixon and Wendy Simmons, PA-C, break down HPP, the often-missed metabolic bone disease. Learn the key red flags, common pitfalls, and how to recognize HPP earlier in your patients: https://lnkd.in/eVShgHXc